Analytical characterization of a novel degradation product in a PEGylated recombinant protein

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 4607-4616

  Zhang, Bing ^a,b   Towers, Edward W ^a   Poppe, Leszek ^a   Cockrill, Steven L ^a  

^a AMGEN INC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Adduct; Analytical biochemistry; Degradation; Mass spectrometry; NMR spectroscopy; PEGylation; Protein structure

Indexed keywords

ALDEHYDE; MACROGOL; PEGYLATED RECOMBINANT PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; ELUTION; GEL PERMEATION CHROMATOGRAPHY; ORTHOGONAL ROTATION; PROTEIN DEGRADATION; PROTEIN STRUCTURE; STORAGE;

EID: 80053265905     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22661     Document Type: Article

References (23)

1. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897-903.
2. Jevsevar S, Kunstelj M, Porekar VG. 2010. PEGylation of therapeutic proteins. Biotechnol J 1:113-128.
3. Jain A, Jain SK. 2008. PEGylation: An approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 25:403-447.
4. Constantinou A, Chen C, Deonarain MP. 2010. Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett 32:609-622.
5. Hamidi M, Azadi A, Rafiei P. 2006. Pharmacokinetic consequences of pegylation. Drug Deliv 13:399-409.
6. Mahmood I, Green MD. 2005. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 44:331-347.
7. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55:1261-1277.
8. Pedder SC. 2003. Pegylation of interferon alfa: Structural and pharmacokinetic properties. Semin Liver Dis 23 Suppl 1:19-22.
9. Kontermann RE. 2009. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23:93-109.
10. Veronese FM, Mero A. 2008. The impact of PEGylation on biological therapies. BioDrugs 22:315-329.
11. Pasut G, Veronese FM. 2009. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc) 45:687-695.
12. Schmidt RJ. 2009. Methoxy polyethylene glycol-epoetin beta: Worth waiting for or a novelty worn off? Expert Opin Pharmacother 10:1509-1514.
13. Duncan R, Kopecek J. 1984. Soluble synthetic polymers as potential drug carriers. Adv Polym Sci. 57:51-101.
14. Hermanson GT, Ed. 2008. Modification with synthetic polymers. In Bioconjugate Techniques. 2nd ed., Boston: Academic Press, pp 936-960.
15. Kang JS, Deluca PP, Lee KC. 2009. Emerging PEGylated drugs. Expert Opin Emerg Drugs 14:363-380.
16. Bailon P, Won CY. 2009. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6:1-16.
17. Goodson RJ, Katre NV. 1990. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (NY) 8:343-346.
18. Morpurgo M, Veronese FM, Kachensky D, Harris JM. 1996. Preparation of characterization of poly(ethylene glycol) vinyl sulfone. Bioconjug Chem 7:363-368.
19. Woghiren C, Sharma B, Stein S. 1993. Protected thiol-polyethylene glycol: A new activated polymer for reversible protein modification. Bioconjug Chem 4:314-318.
20. Molineux G. 2004. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 10:1235-1244.
21. (accessed June 24th, 2010)
22. K.Wüthrich. 1986. NMR of proteins and nucleic acids. New York: John Wiley and Sons.
23. Kim JK, Garripelli VK, Jeong UH, Park JS, Repka MA, Jo S. 2010. Novel pH-sensitive polyacetal-based block copolymers for controlled drug delivery. Int J Pharm 401:79-86.